Investors decide between Lexicon pharmaceuticals (NASDAQ:LXRX) and Pfizer (NYSE: PFE) They face a choice between an emerging, high-growth biotech player and an established global pharmaceutical titan with massive scale.
These two companies operate at opposite ends of the size spectrum: one focuses on specialized precision medicine while the other manages a broad portfolio of vaccines and therapeutics. This comparison explores your recent financial health and risk profiles.
The case of Lexicon Pharmaceuticals
Lexicon Pharmaceuticals operates as a contender among biotech stocks by using genetic science to develop treatments for chronic diseases. The company primarily focuses on its commercial product, INPEFA, while licensing its programs to partners such as Viatris for international markets. Specific customer concentration data was not disclosed in recent filings.
In fiscal 2025, revenue reached nearly $49.8 million, representing approximately 60% growth over the prior year. Despite this improvement, the company reported a net loss of $50.3 million during the period.
In its December 2025 balance sheet, the debt-to-equity ratio was approximately 0.6 times. This ratio compares total debt to shareholders’ equity, indicating the extent to which a company relies on borrowed money.
The case of Pfizer
Pfizer is a global biopharmaceutical leader that discovers, manufactures and distributes medicines and vaccines in approximately 200 countries. With a workforce of nearly 75,000 employees, the company maintains a dominant presence in both developed and emerging markets. Its scale allows it to manage a huge product portfolio simultaneously, although its specific major customers are not revealed in its presentations.
During fiscal 2025, revenue reached approximately $62.6 billion, representing a slight decrease of almost 1.6% from the prior year. The company reported net income of approximately $7.8 billion. This level of profitability translated into a net margin close to 12.4%.
According to the December 2025 balance sheet, the debt-to-equity ratio was approximately 0.8 times. Free cash flow for the fiscal year was approximately $9.1 billion, providing substantial capital for dividends and research.
Comparison of risk profiles
Lexicon Pharmaceuticals faces significant regulatory risks, particularly regarding the approval process for candidates such as ZYNQUISTA for type 1 diabetes. The company also carries an accumulated deficit of nearly $2 billion, which may require additional capital raises on unfavorable terms. Additionally, a single entity, Artal Group, owns approximately 35% of the shares, limiting the influence of smaller retail shareholders.
Pfizer faces significant revenue concentration, with 12 products representing approximately 65% ​​of its total revenue in 2025. The company faces a patent expiration period between 2026 and 2030, which could lead to significant competition from generic drug makers. Additionally, government regulations on pricing and competition from large peers such as Eli Lilly (NYSE:LLY) and merck (NYSE:MRK) could affect long-term profitability.
Valuation comparison
While Lexicon Pharmaceuticals lacks a forward P/E due to its net losses, Pfizer looks much more affordable based on its P/S ratio.
|
Metric
|
Lexicon pharmaceuticals
|
Pfizer
|
Industry benchmark
|
|
Forward P/E
|
n/a
|
8.7x
|
24.9x
|
|
price/earnings ratio
|
16.8x
|
2.3x
|
|
The sector benchmark uses the SPDR XLV Sector ETF.
Valuation metrics come from Financial Modeling Prep (FMP) and may differ from other data providers.
What stocks would you buy in 2026?
Finding a low-priced, development-stage biotech stock that explodes into a 10-bagger stock over the long term with the success of a treatment eventually hitting the market is an investor’s dream. Unfortunately, it usually remains that way: a dream that does not come true. Pharmaceutical companies in the development stage often fail to bring a blockbuster drug to market.
Lexicon Pharmaceuticals is not exactly in a development stage. It has one product on the market, INPEFA, for a once-daily tablet to treat heart failure, but it generated just $1.1 million in sales in the first quarter of 2026. Most of the interest around Lexicon is in the development of drugs for chronic pain and cardiometabolic treatments. There are some positives to trials, but it is always worth keeping in mind that positive trials may still fail to bring a drug to market due to late regulatory rejections or the developer’s belief that the drug will not find much of a market. Lexicon’s low share price, which has traded between $1 and $2.50 since July 2025, indicates the speculative nature of the business.
Pfizer is not a big growth stock, but it is also one of the giants of the pharmaceutical industry. The company suffered something of a post-COVID letdown, as pandemic-related demand slowed, but the business has been flexing its muscles this year. In its first quarter, Pfizer beat Wall Street analysts’ expectations for sales and net income. This is partly because Pfizer has been buying growth: it recently acquired oncology specialist Seagen and posted 20% growth in products from that business. Prifzer is also allocating significant resources to new drug development, with 20 drug development starts scheduled for 2026 and eight data readouts planned, which report on the progress of treatments in development. After falling behind in the GLP-1 weight-loss drug market, Pfizer is also making big strides toward becoming a competitor, with very positive results from Phase II (of III) trials for an injectable GLP-1 reported earlier this year.
With over $6 billion in cash, a forward price-to-earnings ratio of 8.7, and a tasty 7% yield based on its recent price of $26, Pfizer is the choice for 2026.
Should You Buy Lexicon Pharmaceuticals Stock Right Now?
Before buying shares in Lexicon pharmaceuticalsconsider this:
The Motley Fool Stock Advisor The analyst team has just identified what they believe are the 10 best stocks for investors to buy now… and Lexicon pharmaceuticals was not one of them. The 10 stocks that made the cut are designed for long-term growth and could produce monster returns in the years to come.
Consider when netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you would have $442,220!* or when NVIDIA made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you would have $1,230,114!*
That performance is the reason people listen. With a track record of outperforming the S&P 500 by almost 5 times, Stock Advisor offers a clear advantage. Don’t miss the latest Top 10 list, available with Stock Advisorand join an investment community built for the long term.
See the 10 actions »
*Stock Advisor returns from June 11, 2026.
Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool ranks and recommends Eli Lilly, Merck, and Pfizer. The Motley Fool has a disclosure policy.
Lexicon Pharmaceuticals vs. Pfizer: Which Pharma Stocks Are a Better Buy in 2026? was originally published by The Motley Fool
